Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 4, 2011, Pages 834-841

  Liu, Yang ^a   Gao, Xiao Ming ^a   Fang, Lu ^a,b   Jennings, Nicole L ^a   Su, Yidan ^a   Xu, Q ^a   Samson, Andre L ^c   Kiriazis, Helen ^a   Wang, Xin Feng ^a   Shan, Leonard ^a   Sturgeon, Sharelle A ^c   Medcalf, Robert L ^c   Jackson, Shaun P ^c   Dart, Anthony M ^a,b   Du, Xiao Jun ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

inflammation; ischemic heart disease; leukocytes; myocardial infarction; platelets; thienopyridines; ventricular rupture

Indexed keywords

CLOPIDOGREL; MATRIX METALLOPROTEINASE; THIENOPYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR RISK; DRUG EFFICACY; ECHOCARDIOGRAPHY; FLOW CYTOMETRY; HEART INFARCTION; HEART INFARCTION SIZE; HEART VENTRICLE REMODELING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; THROMBOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HEART RUPTURE, POST-INFARCTION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIUM; P-SELECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VENTRICULAR REMODELING;

EID: 79953764113     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.220467     Document Type: Article

References (32)

1. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007;100:27-40. (Pubitemid 46066771)
2. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet- neutrophilinteractions: linking hemostasis and inflammation. Blood Rev. 2007;21: 99-111.
3. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL III, Goldberg RJ, Michelson AD. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001;38:1002-1006. (Pubitemid 32912702)
4. Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation. 2002;105:2166-2171. (Pubitemid 34517160)
5. Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol. 2004;43: 1982-1988. (Pubitemid 38686790)
6. Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med. 2008;5:766-780.
7. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res. 2008;58:88-111.
8. Becker RC, Gore JM, Lambrew C, Weaver WD, Rubison RM, French WJ, Tiefenbrunn AJ, Bowlby LJ, Rogers WJ. A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol. 1996;27:1321-1326. (Pubitemid 26151666)
9. Figueras J, Alcalde O, Barrabes JA, Serra V, Alguersuari J, Cortadellas J, Lidon R-M. Changes in hospital mortality rates in 425 patients with acute ST-elevation myocardial infarction and cardiac rupture over a 30-year period. Circulation. 2008;118:2783-2789.
10. Fang L, Gao XM, Moore XL, Kiriazis H, Su Y, Ming Z, Lim YL, Dart AM, Du XJ. Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. J Mol Cell Cardiol. 2007;43:535-544. (Pubitemid 47615041)
11. Gao XM, Xu Q, Kiriazis H, Dart AM, Du XJ. Mouse model of postinfarct ventricular rupture: time course, strain-and gender-dependency, tensile strength, and histopathology. Cardiovasc Res. 2005;65:469-477. (Pubitemid 40082489)
12. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135-1142. (Pubitemid 29474417)
13. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest. 2005; 115:599-609. (Pubitemid 40322234)
14. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, Topol EJ, Hazen SL, Penn MS. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003;197:615-624. (Pubitemid 36314656)
15. Kameda K, Matsunaga T, Abe N, Fujiwara T, Hanada H, Fukui K, Fukuda I, Osanai T, Okumura K. Increased pericardial fluid level of matrix metalloproteinase-9 activity in patients with acute myocardial infarction: possible role in the development of cardiac rupture. Circ J. 2006;70:673-678. (Pubitemid 43797776)
16. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 1997; 96:778-784. (Pubitemid 27329609)
17. Zidar N, Jeruc J, Balazic J, Stajer D. Neutrophils in human myocardial infarction with rupture of the free wall. Cardiovasc Pathol. 2005;14: 247-250. (Pubitemid 41317271)
18. van den Borne SWM, Cleutjens JPM, Hanemaaijer R, Creemers EE, Smits JFM, Daemen MJAP, Blankesteijn WM. Increased matrix metalloproteinase-8 and-9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol. 2008;18:37-43.
19. Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, Budaj A, Wittlinger T, Fox KA. Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003; 107:966-972. (Pubitemid 36258718)
20. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366:1607-1621.
21. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189. (Pubitemid 40397259)
22. Barrabes JA, Garcia-Dorado D, Mirabet M, Inserte J, Agullo L, Soriano B, Massaguer A, Padilla F, Lidon RM, Soler-Soler J. Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia. J Am Coll Cardiol. 2005;45:293-299. (Pubitemid 40094740)
23. Kupatt C, Wichels R, Horstkotte J, Krombach F, Habazettl H, Boekstegers P. Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion. J Leukoc Biol. 2002;72: 455-461.
24. Xu Y, Huo Y, Toufektsian MC, Ramos SI, Ma Y, Tejani AD, French BA, Yang Z. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;290:H692-H699.
25. Ganame J, Messalli G, Dymarkowski S, Rademakers FE, Desmet W, Van de Werf F, Bogaert J. Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur Heart J. 2009;30:1440-1449.
26. Du XJ, Shan L, Gao XM, Kiriazis H, Liu Y, Lobo A, Head GA, Dart AM. Role of intramural platelet thrombus in the pathogenesis of wall rupture and intra-ventricular thrombosis following acute myocardial infarction. Thromb Haemost. 2011;105:356-364.
27. Santos-Martinez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res. 2008;121:535-542. (Pubitemid 351174273)
28. López-Sendón J, Gurfinkel EP, Lopez de Sa E, Agnelli G, Gore JM, Steg PG, Eagle KA, Cantador JR, Fitzgerald G, Granger CB. Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. Eur Heart J. 2010;31:1449-1456.
29. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104:1533-1537. (Pubitemid 32917347)
30. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res. 2004;61:498-511. (Pubitemid 38210155)
31. Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schömig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation. 2004;110:1916-1919. (Pubitemid 39331901)
32. Dupont AG, Gabriel DA, Cohen MG. Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thromb Res. 2009; 124:6-13.